Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine
Open Access

Distribution and Function of Prostaglandin E2 Receptors in Mouse Uterus: Translational Value for Human Reproduction

Deborah P. Fischer, Anna L. Griffiths, Sylvia Lui, Uzmah J. Sabar, Diane Farrar, Peter J. O’Donovan, David F. Woodward and Kay M. Marshall
Journal of Pharmacology and Experimental Therapeutics June 2020, 373 (3) 381-390; DOI: https://doi.org/10.1124/jpet.119.263509
Deborah P. Fischer
Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna L. Griffiths
Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvia Lui
Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uzmah J. Sabar
Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane Farrar
Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. O’Donovan
Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David F. Woodward
Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kay M. Marshall
Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Visual Overview

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Prostaglandin (PG) E analogs are used clinically to ripen the cervix and induce labor. However, selective receptor agonists may have potential to improve induction response rates or manage unwanted uterine hypercontractility in conditions such as dysmenorrhea and preterm labor. To characterize their therapeutic value, PGE2 analogs were used to investigate the functional E‐type prostanoid (EP) receptor population in isolated human uterus. Responsiveness in mouse tissues was also examined to validate its use as a preclinical model. Uterine samples were obtained from mice at dioestrus (n = 12), term gestation (n = 14), and labor (n = 12) and from the lower uterus of women undergoing hysterectomy (n = 12) or Caesarean section (n = 18). Vehicle and agonist effects were assessed using superfusion and immersion techniques. PGE2 evoked predominant excitatory responses in mouse and relaxation in human tissues. Selective EP4 agonists inhibited tissue activity in both nonpregnant species, while the EP2 mimetic CP533536 also attenuated uterine contractions throughout gestation. The uterotonic effects of the EP3/1 agonist sulprostone were more pronounced than the EP1 agonist ONO-D1-004, corresponding to abundant EP3 receptor expression in all samples. The contractile phenotype in mouse compared with human uteri may relate to regional differences as well as high expression of EP3 receptor transcripts. Similarities in nonpregnant and gestational tissues across species suggest that EP3 may represent a valuable translational drug target for preventing uterine hypercontractility by employing a selective antagonist.

SIGNIFICANCE STATEMENT This research validates the use of nonpregnant mice for preclinical drug discovery of uterine EP receptor targets. To determine the utility of novel drugs and delivery systems at term pregnancy and labor, pharmacological agents interacting with EP3 receptors have clear translational value.

Introduction

Series two prostaglandins (PGs) consist of PGD2, PGE2, PGF2α, prostacyclin, and thromboxane A2. PGE2 exhibits a wide spectrum of physiological and pathological functions in various cells and tissues (Coleman et al., 1994; Sugimoto and Narumiya, 2007) and exerts these effects primarily via four EP receptor subtypes. EP1 and EP3 receptors produce smooth muscle contraction. The EP1 receptor mediates this response through an increase in intracellular calcium (Ca2+), while activation of the EP3 receptor predominantly inhibits smooth muscle relaxation through a decrease in adenylyl cyclase. In contrast, EP2 and EP4 receptors mediate uterine quiescence through the intracellular adenylyl cyclase and cAMP pathway (Sugimoto and Narumiya, 2007). EP1, EP2, EP3, and EP4 have all been isolated and cloned in the mouse (Sugimoto et al., 1992; Honda et al., 1993; Watabe et al., 1993; Nishigaki et al., 1995), revealing the presence of multiple splice variants for EP3 in mice (Sugimoto and Narumiya, 2007) and humans (Matsuoka and Narumiya, 2007) that are evolutionally conserved (Hla, 2005). Their pleiotropic effects are regulated by receptor expression, constitutive activity, signal transduction pathways, and agonist-induced desensitization (Sugimoto and Narumiya, 2007; Markovič et al., 2017) that differ in health and disease.

PGE2 mediates reproductive processes, including ovulation, fertilization, implantation, luteolysis, and uterine contractility (Challis et al., 2002; Valdes et al., 2009). In women, total PG concentrations increase at labor compared with term pregnancy (Durn et al., 2010), with a concurrent rise in intrauterine and amniotic fluid PGE2 release throughout parturition (Lee et al., 2008; Durn et al., 2010). A switch in the activator protein family of transcription factors regulates amniotic PGE2 synthesis and promotes uterine contraction (Lu et al., 2019). Cervical ripening and induction of labor with vaginal, intracervical, or oral PGE2 are recommended to safely expedite neonatal delivery (NICE, 2008; Vogel et al., 2017; Sheibani et al., 2018; Zhao et al., 2019) and reduce stillbirth rates (Hedegaard et al., 2014). However, aberrant PGE2 output and an imbalance in EP gene receptor expression are associated with in vitro fertilization failure (Ruan et al., 2012) preterm labor (Calder, 1990; Gouveia-Figueira et al., 2017) and a lack of response to labor induction (Konopka et al., 2015). Impaired ovulation, fertility, and decreased litter size were displayed in EP2-deficient mice (Hizaki et al., 1999; Kennedy et al., 1999; Tilley et al., 1999). However, the physiological role of each EP subtype in regulating uterine contraction is not well defined.

The aim of this study was to characterize functional EP receptors as potential therapeutic targets in uterine tissues using highly selective agonists. Their temporal and regional expression was examined in the isolated mouse uterus during the oestrous cycle, at term gestation (day 18), and during labor. It was hypothesized that predominant excitatory EP1/3 receptors in the fundus and EP2/4 subtypes in the lower uterus would facilitate caudal contractions for menses and parturition. Efficacy was compared with uterine tissues from nonpregnant and term pregnant women to determine whether the mouse is a suitable system for investigating human uterine biology and pregnancy complications.

Materials and Methods

Experiments on Isolated Mouse Uterine Tissue.

Nonpregnant and pregnant female sexually mature Bankin Kingman White (BKW) mice (B & K Universal Ltd., Hull, UK) housed in groups were used throughout this study. All experimental procedures and animal care were carried out at the University of Bradford in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health, the amended Animals Scientific Procedures Act, UK 2012, and ARRIVE guidelines. The animals had free access to food and water and were exposed to a 12-hour light/12-hour dark cycle. Animals used in gestational studies were mated in a harem of three females to one male. The presence of a vaginal plug was observed as evidence of pregnancy; the day of plug detection was termed day 1 of gestation. The mice were weighed regularly to monitor the progression of pregnancy.

The mice were humanely killed by cervical dislocation when nonpregnant (n = 12), at day 18 of gestation (n = 14), or during labor (one to two pups delivered; n = 12). The uterus was dissected from the body, and uterine samples were taken from different anatomic segments along the length of each uterine horn (Griffiths et al., 2006). In nonpregnant animals, the stage of the oestrous cycle was determined by microscopic examination of the vaginal lavage (McLean et al., 2012). In the pregnant and laboring mice, the fetuses were carefully removed from the uterus and were sacrificed by carbon dioxide inhalation.

Uterine samples were immediately set up for superfusion as previously described (Griffiths et al., 2006). In brief, the strips were attached to isometric force transducers under a resting tension of 2 g, and aerated Krebs’ solution (95% O2/5% CO2) was driven through heating coils (37°C) at a rate of 2 ml/minute (Griffiths et al., 2006). The isolated uterine samples were equilibrated for 30 minutes before the start of drug treatments.

In uterine tissue samples from nonpregnant animals and those taken at late gestation, spontaneous activity diminished after 30 minutes. It was, therefore, difficult to examine the inhibitory effects of the agonists. The inclusion of 5-hydroxytryptamine (5-HT) at 10−6 M to the perfusate reservoir, which enhances acetylcholine and Ca2+ release (Griffiths, 2007), produced uniform, regular myogenicity, allowing the inhibitory properties of the compounds to be explored. Tissue taken during labor displayed a sustained level of activity, so 5-HT was not included in the reservoir for these strips.

PGE2 and the following selective EP agonists were used: ONO-D1-004, a selective EP1 agonist (Oka et al., 2003); the selective EP2 agonists butaprost (Gardiner, 1986) and CP533536 (Li et al., 2003; Paralkar et al., 2003); sulprostone, an EP1 and EP3 receptor agonist (Schaaf et al., 1981); and the EP4 agonists lactam derivative of 8-aza-11-deoxy-PGE1 (LAC-PGE) (Elworthy et al., 2004) and L-902688 (Billot et al., 2003). They were directly administered into the superfusate as 10 μl bolus doses (10−11–10−7 mol) at 10-minute intervals or until baseline activity had resumed. Agonists were administered immediately after a spontaneous contraction to avoid superimposing responses on background activity; this did not apply if there was no background activity present. Time-matched vehicle controls were also assigned, and only one dose-response curve was performed per tissue. At the end of each experiment, the Krebs’ superfusate was replaced with distilled water (Popat and Crankshaw, 2001); this induced a reference contraction (hypotonic shock) that was unique to each tissue strip.

Experiments on Isolated Human Uterine Tissue.

Lower segment myometrial biopsies were obtained from premenopausal women undergoing hysterectomy for benign disorders, such as fibroids, pelvic pain, and heavy menstrual bleeding (aged 26–44; follicular stage; n = 12). At the time of surgery, none of the donors were using oral contraceptives or had received any hormone therapy. Segments of the upper margin of lower uterine muscle were also obtained at Caesarean section from healthy term pregnant women (aged 22–38; 37–40 weeks) not in labor (n = 10) or during active labor (regular contractions, cervical dilation 3–8.5 cm; n = 8). Indications included previous Caesarean section (n = 12), breech presentation (n = 2), fetal distress (n = 2), and prolonged labor (n = 2), none of which influenced in vitro phasic contractions (data not shown). Women who were taking regular prescription medication, who were with multiple fetuses, or who were associated with any major complication of pregnancy, such as hypertension, pre-eclampsia, and diabetes, were excluded from this study. Uterine specimens were obtained from the Yorkshire Clinic, Bradford, and Bradford Royal Infirmary; all women provided informed written consent prior to surgery. Ethical approval for all studies was obtained from the National Research Ethics Committee (LREC: 07/H1306/98).

Human uterine samples were prepared for immersion within an hour of collection as previously described (Fischer et al., 2008). In brief, myometrial strips (10 × 2 × 3 mm), trimmed of endometrial, serosal, fat, and fibrous tissue, were set up in organ baths containing oxygenated Krebs’ solution (95% O2, 5% CO2, 37°C) and attached to isometric force transducers under a resting tension of 2 g (Senior et al., 1991; Senior et al., 1993). Tissues from nonpregnant and term pregnant donors were equilibrated for at least 90 and 120 minutes, respectively, or until regular phasic contractions had developed. Vehicle and cumulative concentration-effect curves for PGE2 and EP agonists (10−10–10−5 M) were added at 30-minute intervals, and only one treatment was assigned per tissue. Responses were expressed as a percentage of hypotonic shock, induced by displacing the Krebs’ solution with distilled water (Popat and Crankshaw, 2001).

Measurement of Responses.

Uterine activity was measured via isometric force transducers (Grass Instruments Inc., RI, USA) linked to PowerLab hardware (AD Instruments Ltd., Dunedin, New Zealand). PowerLab was connected to a PC, and Chart 5 for Windows (AD Instruments Ltd., Dunedin, New Zealand) was used to display the changes in tissue tension. The integrated area under the curve was measured for 5 and 30 minutes after drug administration for mouse (Griffiths et al., 2006) and human (Fischer et al., 2008) tissues, respectively, and was expressed as a percentage of the hypotonic shock reference contraction. Superfusion was suitable for highly contractile mouse tissues (measured as moles within the Krebs’ superfusate), whereas the immersion technique better suited slow phasic human myometrial activity (measured as Molar in a defined 8 ml organ bath volume). Both are commonly used comparable methods for receptor characterization (Hillock and Crankshaw, 1999; Popat and Crankshaw, 2001; Duckworth et al., 2002; Griffiths et al., 2006; Fischer et al., 2008).

Real-Time Reverse-Transcription Polymerase Chain Reaction Analysis.

Total RNA was extracted from snap frozen mouse uterine tissues using TRIzol reagent (Invitrogen Life Technologies, Paisley, UK) followed by the mirVana miRNA isolation Kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturers’ instructions. RNA (1 μg) was converted into cDNA (QuantiTect Reverse Transcription kit; Qiagen, Manchester, UK), and gene expression of β-actin (NM_007393), glyceraldehyde-3-phosphate (GAPDH; NM_008084), EP1 (NM_013641), EP2 (NM_008964), EP3 (NM_011196), and EP4 receptors (NM_001136079) in uteri from nonpregnant, pregnant, and laboring mice were quantified by real-time reverse-transcription polymerase chain reaction (qRT-PCR). The probes for each gene (Qiagen, Manchester, UK) were used in combination with the QuantiTect SYBR Green Supermix (Qiagen, Manchester, UK) on a Quantstudio 12K flex real-time PCR system (Applied Biosystems, Paisley, UK). Absolute gene transcription was normalized to β-actin and GAPDH, and the relative values compared with internal controls shown.

Statistical Analysis.

Data were first tested for normality using a Shapiro-Wilk test. Changes in contractile activity and gene expression were determined using two-way ANOVA with Tukey’s post hoc test (GraphPad Prism 8.0 software; San Diego, CA). Where data were nonparametric, a Friedman’s two-way ANOVA with post hoc test was performed (SPSS version 22; NY). A probability of P < 0.05 was considered to be significant.

Compounds.

5-HT was obtained from Sigma Aldrich Chemical Co. (Poole, Dorset, UK). Butaprost, PGE2, and sulprostone were obtained from Cayman Chemicals (distributed by Alexis Corporation (UK) Ltd., Bigham, Notts, UK). LAC-PGE (7-2-[(E)-3-hydroxy-4-((3-trifluoromethyl-phenyl)-phenyl)-but-1-enyl]-5-oxo-pyrrolidin-1-yl-heptanoic acid), CP533536, ONO-D1-004, and L-902688 were received from Allergan Inc. (Irvine, CA, USA) as gifts. Stock solutions of 10−2 M were prepared by dissolving the compounds in ethanol. Further dilutions were made with 0.9% (w/v) normal saline. The Krebs’ solution (pH 7.4) was freshly prepared at the following composition (mM): NaCl 118.9; KCl 4.7; KH2PO4 1.2; MgSO4 1.2; and CaCl2 2.5, NaHCO3 25.0, and glucose 10.0, oxygenated with 95% O2 and 5% CO2.

Results

Effect of PGE2 on Myometrial Activity.

In all murine tissues, PGE2 evoked a dose-dependent excitation curve. In both upper (Fig. 1A) and lower (Fig. 1B) uterine segments, a greater excitatory response to PGE2 was observed in tissues taken during gestation compared with dioestrus (P < 0.05 to P < 0.001). Preliminary studies showed that this PGE2 effect was similar in tissues taken throughout the oestrous cycle (Supplemental Fig. 1). With PGE2 at 10−11 mol, lower segment tissue taken at labor exhibited a greater contractile response than tissue taken on day 18 of gestation (P < 0.05). When responses to PGE2 in lower and upper tissue segments were compared at each gestational stage, no significant regional variation was observed along the length of the uterine horns.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Dose-response curves (10−11–10−7 mol) and typical traces for PGE2 in (A) upper and (B) lower segments of mouse uterine horn. Matching tissues were obtained from nonpregnant (n = 6), pregnant (gestation day 18; n = 7), and laboring mice (n = 8). Tissue strips were superfused with Krebs’ solution. Activity was determined over 5-minute periods (area under the curve) and expressed as percentage of a reference contraction induced by hypotonic shock. Data are expressed as arithmetic means ± S.E.M., and statistical significance was determined by two-way ANOVA with Tukey’s post hoc test. **P < 0.01; ***P < 0.001 for nonpregnant compared with gestation day 18; †P < 0.05; †† P < 0.01; †††P < 0.001 for nonpregnant compared with labor; #P < 0.05 for gestation day 18 compared with labor.

Human lower segment myometrial strips exhibited strong spontaneous contractions when taken during the follicular phase and at term pregnancy before labor. In these tissues, PGE2 caused predominant utero-relaxant effects (10−10–10−6 M), with tissue activity partially restored at 10−5 M (Fig. 2). Spontaneous contractions approximately halved during labor. PGE2 fully inhibited this myogenicity in a monophasic concentration-related manner by suppressing contractile amplitude (P < 0.001).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Concentration-effect curves (10−10–10−5 M) and typical traces for PGE2 in isolated lower segment myometrium obtained from nonpregnant (n = 11), term pregnant, not in labor (n = 6), and laboring women (n = 4). Tissue strips were immersed in Krebs’ solution. Activity was determined over 30-minute periods (area under the curve) and expressed as percentage of a reference contraction induced by hypotonic shock. Data are shown as arithmetic means ± S.E.M., and statistical significance was determined by two-way ANOVA with Tukey’s post hoc test. *P < 0.05; **P < 0.01 for nonpregnant compared with term pregnant; †P < 0.05; †††P < 0.001 for nonpregnant compared with labor; ##P < 0.01; ###P < 0.001 for term pregnant compared with labor.

Effect of EP2 Agonists on 5-HT–Induced and Spontaneous Myometrial Activity.

The EP2 agonist butaprost did not inhibit 5-HT–induced myogenicity in nongestational and gestational mouse tissues or spontaneous contractions in uterine strips taken during labor (Fig. 3A). Similarly, the nonprostanoid EP2 agonist CP533536 had no effect on 5-HT–driven activity in tissues taken on day 18 of gestation. In tissues taken during dioestrus and labor, CP533536 attenuated both 5-HT–induced and spontaneous myometrial contractions by 52% and 83%, respectively (P < 0.05).

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Vehicle and dose-response curves for EP2 receptor agonists butaprost and CP533536 in uterine samples taken from (A) mice at (i) dioestrus (n = 6), (ii) gestation day 18 (n = 6–8), and (iii) during labor (n = 3–5) as well as from (B) human donors in (i) the follicular phase (n = 6–9), (ii) term pregnancy (n = 6), and (iii) during labor (n = 4–6). Upper segment uteri from mice were superfused, and lower myometrial biopsies from women were immersed in Krebs’ solution. Responses are shown as percentage of a reference contraction induced by hypotonic shock. Data are expressed as arithmetic mean ± S.E.M., and statistical significance was determined by two-way ANOVA with Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001 for vehicle compared with butaprost; ††P < 0.01; †††P < 0.001 for vehicle compared with CP533536.

In immersed lower segment myometrium from nonpregnant and pregnant women, both butaprost and CP533536 caused a gradual decline in contractility compared with vehicle (P < 0.01 to P < 0.001; Fig. 3B). Potency values were similar for both EP2 mimetics (pEC50: 6.7 ± 0.4 and 6.5 ± 0.5 M, respectively). Complete cessation of activity was achieved in many tissue strips at 10−5 M, especially when taken during labor.

Effect of EP4 Agonists on 5-HT–Induced and Spontaneous Myometrial Activity.

The EP4 agonists evoked dose-dependent inhibition of 5-HT–induced myogenicity in mouse tissues obtained in the nongravid state (P < 0.01; Fig. 4A), with L-902688 more potent than LAC-PGE. In gestational uteri, L-902688 had no effect on 5-HT or spontaneously driven uterine contractions. However, bolus doses of LAC-PGE produced a biphasic excitatory response followed by a period of inhibition. When compared with vehicle, LAC-PGE enhanced contractility in tissues taken on day 18 of gestation (P < 0.05).

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Vehicle and dose-response curves for EP4 receptor agonists LAC-PGE and L-902688 in uterine samples taken from (A) mice at (i) dioestrus (n = 6), (ii) gestation day 18 (n = 6–7), and (iii) during labor (n = 3–4) as well as from (B) human donors in (i) the follicular phase (n = 3–7), (ii) term pregnancy (n = 3–6), and (iii) during labor (n = 3–5). Upper segment uteri from mice were superfused, and lower myometrial biopsies from women were immersed in Krebs’ solution. Responses are shown as percentage of a reference contraction induced by hypotonic shock. Data are expressed as arithmetic mean ± S.E.M., and statistical significance was determined by two-way ANOVA with Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001 for vehicle compared with LAC-PGE; †P < 0.05; ††P < 0.01 for vehicle compared with L-902688; #P < 0.05 for LAC-PGE compared with L-902688.

The concentration-effect curves for LAC-PGE and L-902688 exhibited different responses in isolated human myometrium. When taken during the follicular phase, both EP4 agonists gradually reduced myogenic activity compared with time-matched vehicles (P < 0.05 to P < 0.001); at 10−6 M, responses to LAC-PGE plateaued (Fig. 4B). LAC-PGE induced a similar biphasic response at term pregnancy (P < 0.05) but not during labor. Despite a decrease at 10−5 M, L-902688 had no significant effect on myometrial tonus or contractility.

Effect of EP1/3 Agonists on Myometrial Activity.

The EP3/1 agonist sulprostone and EP1 agonist ONO-D1-004 evoked excitation in all murine tissues. Sulprostone produced greater contractile effects than both ONO-D1-004 (P < 0.05 to P < 0.01) and PGE2 (P < 0.05 to P < 0.01) in nonpregnant tissues (Fig. 5A). In uterine tissue taken on day 18 of gestation and during labor, PGE2 and sulprostone were more potent than ONO-D1-004 (P < 0.05 to P < 0.001). The excitatory effects of sulprostone and ONO-D1-004 were higher in gestational over nongestational tissues.

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Dose-response curves for PGE2, the EP3/1 receptor agonist sulprostone and the EP1 receptor agonist ONO-D1-004 in uterine samples taken from (A) mice at (i) dioestrus (n = 11–12), (ii) gestation day 18 (n = 5–7), and (iii) during labor (n = 5–8) as well as from (B) human donors in (i) the follicular phase (n = 3–8), (ii) term pregnancy (n = 4–10), and (iii) during labor (n = 3–7). Upper segment uteri from mice were superfused, and lower myometrial biopsies from women were immersed in Krebs’ solution. Responses are shown as percentage of a reference contraction induced by hypotonic shock. Data are expressed as arithmetic mean ± S.E.M., and statistical significance was determined by two-way ANOVA with Bonferroni’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001 for PGE2 compared with sulprostone; †P < 0.05; ††P < 0.01; †††P < 0.001 for sulprostone compared with ONO-D1-004; #P < 0.05; ##P < 0.01; ###P < 0.001 for PGE2 compared with ONO-D1-004.

In myometrium from nonpregnant, term pregnant, and laboring women, ONO-D1-004 had no effect on phasic contractions (Fig. 5B). Sulprostone evoked excitatory responses compared with ONO-D1-004 and PGE2 (P < 0.01 to P < 0.001). The induced rise in activity compared with vehicle (12.5%, 9.4%, and 12.6%, respectively) corresponded to intensified frequency and amplitude of contractions.

Abundance and Distribution of EP Receptors in Mouse Uterus.

Gene expression of each EP receptor transcript was equivalent in upper and lower regions of the isolated nonpregnant, term pregnant, and laboring mouse uterus (Fig. 6). Detection of EP1 mRNA was relatively low but peaked at term pregnancy compared with tissues taken at dioestrus (P < 0.01) and during labor (P < 0.05). In contrast, abundant EP3 compliments were notable in all uterine samples, especially in the nongravid uterus. Relative EP3 expression decreased with advancing gestation (P < 0.001); interestingly, this was not consistent with its contractile effects (Fig. 5A). A reduction in EP2 (P < 0.01) and EP4 (P < 0.05) receptors was also observed in gestational tissues, better reflecting their agonist-induced effects (Fig. 3A; Fig. 4A).

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Expression of (A) EP1, (B) EP2, (C) EP3, and (D) EP4 transcripts in upper and lower mouse uterus taken at dioestrus (NP; n = 5), term gestation day 18 (P; n = 5), and during labor (L; n = 5). Total RNA was extracted using the TRIzol method and quantified using real-time reverse-transcription PCR, and gene expression was normalized against β-actin and GAPDH relative to an internal control. Data are shown as the median and interquartile range and analyzed using a Friedman’s two-way ANOVA with Dunn’s multiple comparisons post hoc test; *P < 0.05; **P < 0.01; ***P < 0.001 for upper and ††P < 0.01 for lower uterus from nonpregnant mice compared with gestational tissues; and #P < 0.05 for upper and ‡P < 0.05 for lower uterus from gestation day 18 mice compared with laboring tissues.

Discussion

These studies confirm the presence of a functionally heterogeneous EP receptor population in mouse and human uteri, which was characterized for the first time across gestational states. It was discovered that EP3-mediated excitation predominates with uterotonic effects enhanced in the late gestational and laboring uterus, indicating the EP3 receptor as a therapeutic target in women’s reproductive health.

PGE2 has previously been shown to exhibit diverse effects on smooth muscle contractility via EP1-4 subtypes (Coleman et al., 1994). In this study, EP receptor agonist effects varied according to hormonal milieu, most likely because of the differential regulation of EP3 receptors that play an important role in the labor process. Limited EP2 receptor agonist function in mouse but not human tissues substantiate previous findings that murine EP2 mRNA was localized to luminal epithelial cells rather than uterine myocytes (Lim and Dey, 1997; Yang et al., 1997). This suggests that changes in the spatial and temporal expression of EP receptors may mediate uterine events during the oestrous and menstrual cycle, pregnancy, and parturition.

Maintained excitatory response to PGE2 along the length of the mouse uterine horn reflects the relatively uniform EP receptor complements in nongestational and gestational tissues. However, in human myometrium, the expression and ratio of EP subtypes were shown to differ. While the expression of EP1 and EP4 transcripts remain constant throughout the uterus, EP2 receptors increased toward the cervix, whereas EP3 receptors were reported to be the same (Arulkumaran et al., 2012) or more abundant in the upper uterine segment (Astle et al., 2005; Grigsby et al., 2006). Predominant PGE2 tissue excitation in the mouse uterus is likely to represent upper segment function in women. In litter-bearing mice, this may indicate its role to deliver multiple fetuses. It is possible that the uterine body distal to the uterine horns is more translational to the lower segment in women. The clinical implications of sampling upper uterine tissue and ethical restrictions limiting sampling to the lower human uterus prevented the investigation of regional differences.

Because of the decline in spontaneous activity in myometrial strips obtained from nonpregnant and pregnant (gestation day 18) mice (Griffiths, 2007), 5-HT was used to drive in vitro phasic contractions. The biphasic response to PGE2 observed in the 5-HT–induced nongravid tissues indicated the presence of both inhibitory and excitatory EP receptors. These findings were supported by functional studies using the isolated porcine (Cao et al., 2005) and human uterus (Senior et al., 1991).

To identify the functional population of inhibitory EP receptors, selective EP2 and EP4 agonists were used in this study. The EP2 agonists butaprost (Gardiner, 1986) and CP533536 (Li et al., 2003; Paralkar et al., 2003) are well documented for high selectivity at the EP2 receptor with respective Ki values of 110 and 50 nM (Kiriyama et al., 1997; Li et al., 2003; Paralkar et al., 2003). Even so, butaprost showed no significant effects in mice, while CP533536 only attenuated myometrial activity at the highest dose. This suggests a paucity of functional uterine EP2 receptors, which corresponded to findings in the guinea pig (Lebel et al., 2004). However, EP2 mRNA expression was shown to increase during pregnancy and decline at term labor in the rat uterus (Brodt-Eppley and Myatt, 1998; Dong and Yallampalli, 2000). Furthermore, in isolated human myometrium, responsiveness to PGE2 is thought to be primarily mediated via the EP2 receptor (Senior et al., 1991; Senior et al., 1993; Duckworth et al., 2002; Fischer et al., 2008) and cAMP signaling (Sooranna et al., 2005), with its expression altered in a temporal and regional manner. Myometrial EP2 receptors decrease toward term gestation (Matsumoto et al., 1997; Brodt-Eppley and Myatt, 1999; Leonhardt et al., 2003) and are reported to not change (Dong and Yallampalli, 2000; Lebel et al., 2004; Kandola et al., 2014) or increase during parturition (Grigsby et al., 2006). The expression of EP2 receptors is also more intense in the lower rather than upper human uterine segments (Astle et al., 2005; Grigsby et al., 2006). This may explain similar EP2-mediated effects in this study, contributing to the relaxant phenotype of the lower uterus during parturition for successful neonatal delivery.

In contrast, EP4 receptors in mouse uterus showed gestational but not regional-related changes. The pharmacological effects of LAC-PGE and L-902688 diminished during pregnancy and labor, following the EP4 expression profile. At term gestation, tissue excitation evoked by LAC-PGE may be attributed to off-target activation of EP3 receptors (Maruyama et al., 2001). L-902688 produced the greatest inhibition and was reported to be 3 to 5 times more potent than PGE2 (Billot et al., 2003). EP4 receptors were also consistently expressed in human uterus (Astle et al., 2005; Grigsby et al., 2006) and were reported to have a negligible function (Hillock and Crankshaw, 1999). The LAC-PGE analog used in this study displayed utero-relaxant effects, possibly because of its high affinity and 1000-fold subtype selectivity for EP4 (Ki: 4.5 nM) (Elworthy et al., 2004) compared with the previously studied EP4 receptor antagonist AH23848B (Ki: 2690 nM) (Davis and Sharif, 2000). Even so, efficacy was low, especially at term gestation and labor, substantiating that inhibitory receptors are predominantly of the EP2 subtype. Because of its involvement in cervical ripening (Schmitz et al., 2001), EP4 receptors may have a distinct role from modulating uterine contractions in mouse and human uteri at term.

Despite predominant human uterine quiescence, responses evoked by PGE2 suggest the presence of contractile EP receptor subtypes in all tissue types. EP3 receptor mRNA is highly expressed in the mouse uterus (Sugimoto et al., 1992) and has been detected on uterine smooth muscle cells (Katsuyama et al., 1997; Yang et al., 1997). However, there are conflicting reports concerning the EP1 subtype with either low (Yang et al., 1997) or undetectable levels of mRNA identified (Katsuyama et al., 1997), perhaps relating to the nuclear sequestration of EP1 during labor (Arulkumaran et al., 2012). ONO-D1-004, which is a specific EP1 agonist, has been shown to be eightfold less potent than PGE2 (Oka et al., 2003). Nevertheless, in this study, PGE2 and ONO-D1-004 evoked analogous uterotonic responses in isolated tissue from nonpregnant animals. Sulprostone, an EP3/1 agonist, augmented uterine contractility, indicating EP1 and EP3 receptor function. Given that PGE2 binds to its receptor subtypes with a rank order of affinity of EP3 > EP4 > EP2 > EP1 (Kiriyama et al., 1997), its contractile effects may have been moderated by its actions on inhibitory EP receptors. Even so, unlike the hypothesis, EP3 receptors appear to have a greater role.

In mice, tissue excitation was upregulated in late gestational compared with nongestational tissues. While overall expression was lower, proportionally EP3 receptors were threefold higher than EP2 and EP4 subtypes at term pregnancy and labor than in the nonpregnant uterus. Because of the excitatory profile maintained during labor, it is likely that EP3 receptors are involved in the contractile force associated with parturition. In human, baboon, and guinea-pig myometrium at term pregnancy and labor, EP3 receptor expression was similarly reported to be greater than that of EP2 and EP4 receptors (Matsumoto et al., 1997; Smith et al., 2001; Terry et al., 2008). This provides support to exploit EP3 receptors as a potential target for tocolysis or improved labor induction. Antagonizing EP3 receptors also shows pharmacological promise through their apparent antithrombotic and antiulcer effects, which are currently under clinical evaluation (Markovič et al., 2017; Xiang et al., 2019).

In conclusion, a heterogeneous EP receptor population characterized in mouse and human female reproductive tracts showed some similarities. In lower segment nongestational tissues, both EP4 and EP2 receptor agonists suppressed uterine activity without affecting resting tone. Their contrasting tocolytic potential at term pregnancy perhaps reflected uterine topography. In all tissues, EP3-mediated excitation seemed to predominate with uterotonic effects enhanced in the late gestational and laboring uterus. These findings support development of new selective EP3 receptor modalities, which are currently being investigated for local drug delivery. Examining their effects in mice offers valuable preclinical insight that could be used to improve response rates for labor induction or as a therapy for menstrual cramps, pelvic pain, or preterm labor caused by uterine hypercontractility.

Acknowledgments

The authors would like to thank Allergan Inc. for their generous supply of compounds and for supporting D.P.F., A.L.G., and U.J.S.

Authorship Contributions

Participated in research design: Fischer, Griffiths, Lui, Woodward, Marshall.

Conducted experiments: Fischer, Griffiths, Lui.

Contributed new reagents or analytical tools: Woodward, Marshall.

Performed data analysis: Fischer, Griffiths.

Wrote or contributed to the writing of the manuscript: Fischer, Griffiths, Sabar, Farrar, O’Donovan, Woodward, Marshall.

Footnotes

    • Received October 30, 2019.
    • Accepted March 10, 2020.
  • ↵1 D.P.F. and A.L.G. contributed equally.

  • https://doi.org/10.1124/jpet.119.263509.

  • ↵Embedded ImageThis article has supplemental material available at jpet.aspetjournals.org.

Abbreviations

5-HT
5-hydroxytryptamine
Ca2+
calcium EP prostaglandin E2 receptor
GAPDH
glyceraldehyde-3-phosphate
LAC-PGE
lactam derivative of 8-aza-11-deoxy-PGE1
PCR
polymerase chain reaction
PG
prostaglandin
  • Copyright © 2020 by The Author(s)

This is an open access article distributed under the CC BY-NC Attribution 4.0 International license.

References

  1. ↵
    1. Arulkumaran S,
    2. Kandola MK,
    3. Hoffman B,
    4. Hanyaloglu AC,
    5. Johnson MR, and
    6. Bennett PR
    (2012) The roles of prostaglandin EP 1 and 3 receptors in the control of human myometrial contractility. J Clin Endocrinol Metab 97:489–498.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Astle S,
    2. Thornton S, and
    3. Slater DM
    (2005) Identification and localization of prostaglandin E2 receptors in upper and lower segment human myometrium during pregnancy. Mol Hum Reprod 11:279–287.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Billot X,
    2. Chateauneuf A,
    3. Chauret N,
    4. Denis D,
    5. Greig G,
    6. Mathieu MC,
    7. Metters KM,
    8. Slipetz DM, and
    9. Young RN
    (2003) Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med Chem Lett 13:1129–1132.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Brodt-Eppley J and
    2. Myatt L
    (1998) Changes in expression of contractile FP and relaxatory EP2 receptors in pregnant rat myometrium during late gestation, at labor, and postpartum. Biol Reprod 59:878–883.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Brodt-Eppley J and
    2. Myatt L
    (1999) Prostaglandin receptors in lower segment myometrium during gestation and labor. Obstet Gynecol 93:89–93.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Calder AA
    (1990) Prostaglandins as therapy for labour induction or therapeutic abortion. Reprod Fertil Dev 2:553–556.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Cao J,
    2. Yosida M,
    3. Kitazawa T, and
    4. Taneike T
    (2005) Uterine region-dependent differences in responsiveness to prostaglandins in the non-pregnant porcine myometrium. Prostaglandins Other Lipid Mediat 75:105–122.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Challis JR,
    2. Sloboda DM,
    3. Alfaidy N,
    4. Lye SJ,
    5. Gibb W,
    6. Patel FA,
    7. Whittle WL, and
    8. Newnham JP
    (2002) Prostaglandins and mechanisms of preterm birth. Reproduction 124:1–17.
    OpenUrlAbstract
  9. ↵
    1. Coleman RA,
    2. Smith WL, and
    3. Narumiya S
    (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205–229.
    OpenUrlPubMed
  10. ↵
    1. Davis TL and
    2. Sharif NA
    (2000) Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. Br J Pharmacol 130:1919–1926.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Dong YL and
    2. Yallampalli C
    (2000) Pregnancy and exogenous steroid treatments modulate the expression of relaxant EP(2) and contractile FP receptors in the rat uterus. Biol Reprod 62:533–539.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Duckworth N,
    2. Marshall K, and
    3. Clayton JK
    (2002) An investigation of the effect of the prostaglandin EP2 receptor agonist, butaprost, on the human isolated myometrium from pregnant and non-pregnant women. J Endocrinol 172:263–269.
    OpenUrlAbstract
  13. ↵
    1. Durn JH,
    2. Marshall KM,
    3. Farrar D,
    4. O’Donovan P,
    5. Scally AJ,
    6. Woodward DF, and
    7. Nicolaou A
    (2010) Lipidomic analysis reveals prostanoid profiles in human term pregnant myometrium. Prostaglandins Leukot Essent Fatty Acids 82:21–26.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Elworthy TR,
    2. Kertesz DJ,
    3. Kim W,
    4. Roepel MG,
    5. Quattrocchio-Setti L,
    6. Smith DB,
    7. Tracy JL,
    8. Chow A,
    9. Li F,
    10. Brill ER, et al.
    (2004) Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization. Bioorg Med Chem Lett 14:1655–1659.
    OpenUrlPubMed
  15. ↵
    1. Fischer DP,
    2. Hutchinson JA,
    3. Farrar D,
    4. O’Donovan PJ,
    5. Woodward DF, and
    6. Marshall KM
    (2008) Loss of prostaglandin F2alpha, but not thromboxane, responsiveness in pregnant human myometrium during labour. J Endocrinol 197:171–179.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Gardiner PJ
    (1986) Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979. Br J Pharmacol 87:45–56.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Gouveia-Figueira S,
    2. Martens DS,
    3. Nawrot TS, and
    4. Nording ML
    (2017) Cord blood eicosanoid signatures and newborn gestational age. Prostaglandins Other Lipid Mediat 133:123–127.
    OpenUrl
  18. ↵
    1. Griffiths AL
    (2007) The influence of the hormonal milieu on uterine prostaglandin EP, FP and TP-receptor populations. PhD Thesis, University of Bradford.
  19. ↵
    1. Griffiths AL,
    2. Marshall KM,
    3. Senior J,
    4. Fleming C, and
    5. Woodward DF
    (2006) Effect of the oestrous cycle, pregnancy and uterine region on the responsiveness of the isolated mouse uterus to prostaglandin F(2alpha) and the thromboxane mimetic U46619. J Endocrinol 188:569–577.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Grigsby PL,
    2. Sooranna SR,
    3. Adu-Amankwa B,
    4. Pitzer B,
    5. Brockman DE,
    6. Johnson MR, and
    7. Myatt L
    (2006) Regional expression of prostaglandin E2 and F2alpha receptors in human myometrium, amnion, and choriodecidua with advancing gestation and labor. Biol Reprod 75:297–305.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hedegaard M,
    2. Lidegaard Ø,
    3. Skovlund CW,
    4. Mørch LS, and
    5. Hedegaard M
    (2014) Reduction in stillbirths at term after new birth induction paradigm: results of a national intervention. BMJ Open 4:e005785.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Hillock CJ and
    2. Crankshaw DJ
    (1999) Inhibitory prostanoid EP receptors in human non-pregnant myometrium. Eur J Pharmacol 378:99–108.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Hizaki H,
    2. Segi E,
    3. Sugimoto Y,
    4. Hirose M,
    5. Saji T,
    6. Ushikubi F,
    7. Matsuoka T,
    8. Noda Y,
    9. Tanaka T,
    10. Yoshida N, et al.
    (1999) Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Proc Natl Acad Sci USA 96:10501–10506.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Hla T
    (2005) Genomic insights into mediator lipidomics. Prostaglandins Other Lipid Mediat 77:197–209.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Honda A,
    2. Sugimoto Y,
    3. Namba T,
    4. Watabe A,
    5. Irie A,
    6. Negishi M,
    7. Narumiya S, and
    8. Ichikawa A
    (1993) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J Biol Chem 268:7759–7762.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Kandola MK,
    2. Sykes L,
    3. Lee YS,
    4. Johnson MR,
    5. Hanyaloglu AC, and
    6. Bennett PR
    (2014) EP2 receptor activates dual G protein signaling pathways that mediate contrasting proinflammatory and relaxatory responses in term pregnant human myometrium. Endocrinology 155:605–617.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Katsuyama M,
    2. Sugimoto Y,
    3. Morimoto K,
    4. Hasumoto K,
    5. Fukumoto M,
    6. Negishi M, and
    7. Ichikawa A
    (1997) ‘Distinct cellular localization’ of the messenger ribonucleic acid for prostaglandin E receptor subtypes in the mouse uterus during pseudopregnancy. Endocrinology 138:344–350.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kennedy CR,
    2. Zhang Y,
    3. Brandon S,
    4. Guan Y,
    5. Coffee K,
    6. Funk CD,
    7. Magnuson MA,
    8. Oates JA,
    9. Breyer MD, and
    10. Breyer RM
    (1999) Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 5:217–220.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Kiriyama M,
    2. Ushikubi F,
    3. Kobayashi T,
    4. Hirata M,
    5. Sugimoto Y, and
    6. Narumiya S
    (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122:217–224.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Konopka CK,
    2. Glanzner WG,
    3. Rigo ML,
    4. Rovani MT,
    5. Comim FV,
    6. Gonçalves PB,
    7. Morais EN,
    8. Antoniazzi AQ,
    9. Mello CF, and
    10. Cruz IB
    (2015) Responsivity to PGE2 labor induction involves concomitant differential prostaglandin E receptor gene expression in cervix and myometrium. Genet Mol Res 14:10877–10887.
    OpenUrl
  31. ↵
    1. Lebel W,
    2. Riccardi K,
    3. Grasser WA,
    4. Terry K,
    5. Thompson D, and
    6. Paralkar VM
    (2004) Prostaglandin E2 receptor subtype EP-2 is not involved in the induction of non-pregnant guinea pig uterine contractions associated with terminal pregnancy. Prostaglandins Leukot Essent Fatty Acids 71:399–404.
    OpenUrlPubMed
  32. ↵
    1. Lee SE,
    2. Romero R,
    3. Park IS,
    4. Seong HS,
    5. Park CW, and
    6. Yoon BH
    (2008) Amniotic fluid prostaglandin concentrations increase before the onset of spontaneous labor at term. J Matern Fetal Neonatal Med 21:89–94.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Leonhardt A,
    2. Glaser A,
    3. Wegmann M,
    4. Hackenberg R, and
    5. Nüsing RM
    (2003) Expression of prostanoid receptors in human lower segment pregnant myometrium. Prostaglandins Leukot Essent Fatty Acids 69:307–313.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Li M,
    2. Ke HZ,
    3. Qi H,
    4. Healy DR,
    5. Li Y,
    6. Crawford DT,
    7. Paralkar VM,
    8. Owen TA,
    9. Cameron KO,
    10. Lefker BA, et al.
    (2003) A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res 18:2033–2042.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Lim H and
    2. Dey SK
    (1997) Prostaglandin E2 receptor subtype EP2 gene expression in the mouse uterus coincides with differentiation of the luminal epithelium for implantation. Endocrinology 138:4599–4606.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Lu JW,
    2. Wang WS,
    3. Zhou Q,
    4. Gan XW,
    5. Myatt L, and
    6. Sun K
    (2019) Activation of prostaglandin EP4 receptor attenuates the induction of cyclooxygenase-2 expression by EP2 receptor activation in human amnion fibroblasts: implications for parturition. FASEB J 33:8148–8160.
    OpenUrl
  37. ↵
    1. Markovič T,
    2. Jakopin Ž,
    3. Dolenc MS, and
    4. Mlinarič-Raščan I
    (2017) Structural features of subtype-selective EP receptor modulators. Drug Discov Today 22:57–71.
    OpenUrlCrossRef
  38. ↵
    1. Maruyama T,
    2. Asada M,
    3. Shiraishi T,
    4. Ishida A,
    5. Egashira H,
    6. Yoshida H,
    7. Maruyama T,
    8. Ohuchida S,
    9. Nakai H,
    10. Kondo K, et al.
    (2001) Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity. Bioorg Med Chem Lett 11:2029–2031.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Matsumoto T,
    2. Sagawa N,
    3. Yoshida M,
    4. Mori T,
    5. Tanaka I,
    6. Mukoyama M,
    7. Kotani M, and
    8. Nakao K
    (1997) The prostaglandin E2 and F2 alpha receptor genes are expressed in human myometrium and are down-regulated during pregnancy. Biochem Biophys Res Commun 238:838–841.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Matsuoka T and
    2. Narumiya S
    (2007) Prostaglandin receptor signaling in disease. ScientificWorldJournal 7:1329–1347.
    OpenUrlCrossRefPubMed
  41. ↵
    1. McLean AC,
    2. Valenzuela N,
    3. Fai S, and
    4. Bennett SA
    (2012) Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J Vis Exp e4389.
  42. ↵
    1. NICE
    (2008) Induction of Labour, p 124, National Collaborating Centre for Women's and Children's Health London, UK.
  43. ↵
    1. Nishigaki N,
    2. Negishi M,
    3. Honda A,
    4. Sugimoto Y,
    5. Namba T,
    6. Narumiya S, and
    7. Ichikawa A
    (1995) Identification of prostaglandin E receptor ‘EP2’ cloned from mastocytoma cells EP4 subtype. FEBS Lett 364:339–341.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Oka T,
    2. Oka K, and
    3. Saper CB
    (2003) Contrasting effects of E type prostaglandin (EP) receptor agonists on core body temperature in rats. Brain Res 968:256–262.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Paralkar VM,
    2. Borovecki F,
    3. Ke HZ,
    4. Cameron KO,
    5. Lefker B,
    6. Grasser WA,
    7. Owen TA,
    8. Li M,
    9. DaSilva-Jardine P,
    10. Zhou M, et al.
    (2003) An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci USA 100:6736–6740.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Popat A and
    2. Crankshaw DJ
    (2001) Variable responses to prostaglandin E(2) in human non-pregnant myometrium. Eur J Pharmacol 416:145–152.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Ruan YC,
    2. Guo JH,
    3. Liu X,
    4. Zhang R,
    5. Tsang LL,
    6. Dong JD,
    7. Chen H,
    8. Yu MK,
    9. Jiang X,
    10. Zhang XH, et al.
    (2012) Activation of the epithelial Na+ channel triggers prostaglandin E2 release and production required for embryo implantation. Nat Med 18:1112–1117.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Schaaf TK,
    2. Bindra JS,
    3. Eggler JF,
    4. Plattner JJ,
    5. Nelson AJ,
    6. Johnson MR,
    7. Constantine JW,
    8. Hess HJ, and
    9. Elger W
    (1981) N-(Methanesulfonyl)-16-phenoxyprostaglandincarboxamides: tissue-selective, uterine stimulants. J Med Chem 24:1353–1359.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Schmitz T,
    2. Dallot E,
    3. Leroy MJ,
    4. Breuiller-Fouché M,
    5. Ferré F, and
    6. Cabrol D
    (2001) EP(4) receptors mediate prostaglandin E(2)-stimulated glycosaminoglycan synthesis in human cervical fibroblasts in culture. Mol Hum Reprod 7:397–402.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Senior J,
    2. Marshall K,
    3. Sangha R,
    4. Baxter GS, and
    5. Clayton JK
    (1991) In vitro characterization of prostanoid EP-receptors in the non-pregnant human myometrium. Br J Pharmacol 102:747–753.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Senior J,
    2. Marshall K,
    3. Sangha R, and
    4. Clayton JK
    (1993) In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br J Pharmacol 108:501–506.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Sheibani L,
    2. Raymond K,
    3. Rugarn O, and
    4. Wing DA
    (2018) Associations of hypertensive disorders of pregnancy and outcomes of labor induction with prostaglandin vaginal inserts. Hypertens Pregnancy 37:51–57.
    OpenUrl
  53. ↵
    1. Smith GC,
    2. Wu WX, and
    3. Nathanielsz PW
    (2001) Effects of gestational age and labor on expression of prostanoid receptor genes in baboon uterus. Biol Reprod 64:1131–1137.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Sooranna SR,
    2. Grigsby P,
    3. Myatt L,
    4. Bennett PR, and
    5. Johnson MR
    (2005) Prostanoid receptors in human uterine myocytes: the effect of reproductive state and stretch. Mol Hum Reprod 11:859–864.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Sugimoto Y,
    2. Namba T,
    3. Honda A,
    4. Hayashi Y,
    5. Negishi M,
    6. Ichikawa A, and
    7. Narumiya S
    (1992) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J Biol Chem 267:6463–6466.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Sugimoto Y and
    2. Narumiya S
    (2007) Prostaglandin E receptors. J Biol Chem 282:11613–11617.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Terry KK,
    2. Lebel WS,
    3. Riccardi KA,
    4. Grasser WA,
    5. Thompson DD, and
    6. Paralkar VM
    (2008) Effects of gestational age on prostaglandin EP receptor expression and functional involvement during in vitro contraction of the guinea pig uterus. Prostaglandins Leukot Essent Fatty Acids 78:3–10.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Tilley SL,
    2. Audoly LP,
    3. Hicks EH,
    4. Kim HS,
    5. Flannery PJ,
    6. Coffman TM, and
    7. Koller BH
    (1999) Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J Clin Invest 103:1539–1545.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Valdes G,
    2. Kaufmann P,
    3. Corthorn J,
    4. Erices R,
    5. Brosnihan KB, and
    6. Joyner-Grantham J
    (2009) Vasodilator factors in the systemic and local adaptations to pregnancy. Reprod Biol Endocrinol 7:79.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Vogel JP,
    2. Osoti AO,
    3. Kelly AJ,
    4. Livio S,
    5. Norman JE, and
    6. Alfirevic Z
    (2017) Pharmacological and mechanical interventions for labour induction in outpatient settings. Cochrane Database Syst Rev 9:CD007701.
    OpenUrl
  61. ↵
    1. Watabe A,
    2. Sugimoto Y,
    3. Honda A,
    4. Irie A,
    5. Namba T,
    6. Negishi M,
    7. Ito S,
    8. Narumiya S, and
    9. Ichikawa A
    (1993) Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J Biol Chem 268:20175–20178.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Xiang Q,
    2. Pang X,
    3. Liu Z,
    4. Yang G,
    5. Tao W,
    6. Pei Q, and
    7. Cui Y
    (2019) Progress in the development of antiplatelet agents: focus on the targeted molecular pathway from bench to clinic. Pharmacol Ther 203:107393.
    OpenUrl
  63. ↵
    1. Yang ZM,
    2. Das SK,
    3. Wang J,
    4. Sugimoto Y,
    5. Ichikawa A, and
    6. Dey SK
    (1997) Potential sites of prostaglandin actions in the periimplantation mouse uterus: differential expression and regulation of prostaglandin receptor genes. Biol Reprod 56:368–379.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Zhao L,
    2. Lin Y,
    3. Jiang TT,
    4. Wang L,
    5. Li M,
    6. Wang Y,
    7. Sun GQ, and
    8. Xiao M
    (2019) Vaginal delivery among women who underwent labor induction with vaginal dinoprostone (PGE2) insert: a retrospective study of 1656 women in China. Pharmacol Ther 32:1721–1727.
    OpenUrl
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 373 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 373, Issue 3
1 Jun 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Distribution and Function of Prostaglandin E2 Receptors in Mouse Uterus: Translational Value for Human Reproduction
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Relevance of Mouse Uterus for EP Receptor Characterisation

Deborah P. Fischer, Anna L. Griffiths, Sylvia Lui, Uzmah J. Sabar, Diane Farrar, Peter J. O’Donovan, David F. Woodward and Kay M. Marshall
Journal of Pharmacology and Experimental Therapeutics June 1, 2020, 373 (3) 381-390; DOI: https://doi.org/10.1124/jpet.119.263509

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

Relevance of Mouse Uterus for EP Receptor Characterisation

Deborah P. Fischer, Anna L. Griffiths, Sylvia Lui, Uzmah J. Sabar, Diane Farrar, Peter J. O’Donovan, David F. Woodward and Kay M. Marshall
Journal of Pharmacology and Experimental Therapeutics June 1, 2020, 373 (3) 381-390; DOI: https://doi.org/10.1124/jpet.119.263509
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Efficacy of tralesinidase alfa in a canine model of MPS IIIB
  • Sulindac derivative protects against oxidative damage
  • CNS Delivery of the DNA-PKcs Inhibitor Peposertib
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics